Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs TG Therapeutics, Inc. (TGTX)

Caris Life Sciences,�Inc. and TG Therapeutics, Inc. are both Biotechnology companies. Caris Life Sciences,�Inc. and TG Therapeutics, Inc. are of similar size ($9.0B and $8.6B). TG Therapeutics, Inc. trades at the lower P/E: 17.8× against 81.3×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 96.4% against 76.1%. TG Therapeutics, Inc. has the higher net margin (55.2% vs 8.15%) and the lower return on invested capital (10.7% vs 50.0%). Across the 20 metrics below, Caris Life Sciences,�Inc. leads on 11 and TG Therapeutics, Inc. on 9.

Valuation

Metric CAI TGTX Biotechnology median
P/E 81.30 17.75 8.50
P/S 8.74 9.57 9.71
P/B 14.61 12.67 2.13
Price to free cash flow 69.74 440.11 20.82
EV/EBITDA 45.80 57.69 0.64
EV/Sales 8.33 9.81 9.21
Earnings yield 1.23% 5.63% (33.15%)
Free cash flow yield 1.43% 0.23% (25.50%)

Profitability

Metric CAI TGTX Biotechnology median
Gross margin 69.66% 82.37% 65.16%
Operating margin 15.49% 17.05% 0.00%
Net margin 8.15% 55.22% 0.00%
Free cash flow margin 12.53% 2.17% 0.00%
Return on equity 15.45% 100.28% (56.36%)
Return on assets 7.39% 37.70% (48.04%)
Return on invested capital 49.95% 10.69% 0.00%

Growth

Metric CAI TGTX Biotechnology median
Revenue growth (TTM) 96.36% 76.08% 6.02%
EPS growth (last fiscal year) 59.45% 1,746.67% 30.26%
Revenue growth, 5-year CAGR — 426.73% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI TGTX Biotechnology median
Debt to equity 0.66 1.23 0.00
Current ratio 5.53 4.27 4.72
Net debt to EBITDA (5.23) 0.86 0.96

Dividend

Metric CAI TGTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CAI TGTX Biotechnology median
Market cap 8.98b 8.57b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack